Boston Scientific Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the Class Period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its successful track record, thus investors should choose experienced counsel wisely.
- Investor Action Steps: Investors can visit Rosen Law Firm's website or call the toll-free number for more information on joining the class action, noting that no class has been certified yet, allowing them to choose counsel or remain absent class members.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 62.820
Low
94.00
Averages
108.14
High
132.00
Current: 62.820
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the Class Period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its successful track record, thus investors should choose experienced counsel wisely.
- Investor Action Steps: Investors can visit Rosen Law Firm's website or call the toll-free number for more information on joining the class action, noting that no class has been certified yet, allowing them to choose counsel or remain absent class members.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statements Allegations: The complaint alleges that executives made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, which undermined investor confidence in the company's future.
- Market Impact: The company is reportedly experiencing adverse trends such as declining procedure volumes and increasing competitive pressures, leading plaintiffs to argue that the executives' optimistic projections lacked a reasonable basis, potentially resulting in a stock price decline.
- Investor Actions: Affected investors must apply by May 4, 2026, to be appointed as lead plaintiffs to participate in any potential recovery, with the law firm promising to charge fees only upon success, thereby reducing the financial risk for investors.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Contact
- Legal Action Reminder: Faruq & Faruq LLP is investigating potential claims against Boston Scientific Corporation, specifically urging investors who purchased or acquired securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Investor Rights Protection: Securities Litigation Partner Josh Wilson encourages affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights, demonstrating a commitment to safeguarding investor interests.
- Class Action Progress: Boston Scientific is facing a federal securities class action, and Faruq & Faruq reminds investors to act promptly to secure their rights in the lawsuit, highlighting the urgency of legal proceedings.
- Market Reaction Impact: The potential implications of the legal action may pressure Boston Scientific's stock price, prompting investors to stay informed about developments to make informed investment decisions.
See More
Boston Scientific Class Action Reminder Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing adverse facts about its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record, which investors should consider when selecting legal counsel.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support in the class action.
See More
Investigation into Boston Scientific Securities Litigation Announced
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Boston Scientific, specifically urging investors who purchased securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Performance Miss Impact: Boston Scientific's February 4, 2026, earnings report revealed disappointing U.S. EP sales, resulting in a significant net income miss and a 17.6% drop in stock price to $75.50 per share, causing substantial losses for investors.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives failed to disclose the true state of the U.S. EP segment's growth, leading to a severe loss of investor confidence and negatively impacting market expectations for future performance.
- Legal Rights Reminder: Faruq & Faruq LLP encourages anyone with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to come forward to assist in the litigation process.
See More
Boston Scientific Class Action Lawsuit Notice
- Class Action Timeline: Purchasers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, have until May 4, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor concern over potential legal risks.
- Allegations Overview: The lawsuit alleges that Boston Scientific and its executives made false or misleading statements during the class period, failing to disclose risks from increased market competition and unmet revenue expectations, which could undermine investor confidence.
- Financial Performance Disclosure: On February 4, 2026, Boston Scientific reported fourth-quarter and full-year 2025 results, revealing a net income increase to $672 million, yet the earnings per share (EPS) fell short of guidance, leading to a stock price drop of over 17%, reflecting market apprehension about the company's outlook.
- Legal Representation Information: Investors can apply to become lead plaintiffs through Robbins Geller Rudman & Dowd LLP, a firm with extensive experience in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strength in such cases.
See More
Boston Scientific Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the Class Period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its successful track record, thus investors should choose experienced counsel wisely.
- Investor Action Steps: Investors can visit Rosen Law Firm's website or call the toll-free number for more information on joining the class action, noting that no class has been certified yet, allowing them to choose counsel or remain absent class members.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statements Allegations: The complaint alleges that executives made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, which undermined investor confidence in the company's future.
- Market Impact: The company is reportedly experiencing adverse trends such as declining procedure volumes and increasing competitive pressures, leading plaintiffs to argue that the executives' optimistic projections lacked a reasonable basis, potentially resulting in a stock price decline.
- Investor Actions: Affected investors must apply by May 4, 2026, to be appointed as lead plaintiffs to participate in any potential recovery, with the law firm promising to charge fees only upon success, thereby reducing the financial risk for investors.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Contact
- Legal Action Reminder: Faruq & Faruq LLP is investigating potential claims against Boston Scientific Corporation, specifically urging investors who purchased or acquired securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Investor Rights Protection: Securities Litigation Partner Josh Wilson encourages affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights, demonstrating a commitment to safeguarding investor interests.
- Class Action Progress: Boston Scientific is facing a federal securities class action, and Faruq & Faruq reminds investors to act promptly to secure their rights in the lawsuit, highlighting the urgency of legal proceedings.
- Market Reaction Impact: The potential implications of the legal action may pressure Boston Scientific's stock price, prompting investors to stay informed about developments to make informed investment decisions.
See More
Boston Scientific Class Action Reminder Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing adverse facts about its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record, which investors should consider when selecting legal counsel.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support in the class action.
See More
Investigation into Boston Scientific Securities Litigation Announced
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Boston Scientific, specifically urging investors who purchased securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Performance Miss Impact: Boston Scientific's February 4, 2026, earnings report revealed disappointing U.S. EP sales, resulting in a significant net income miss and a 17.6% drop in stock price to $75.50 per share, causing substantial losses for investors.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives failed to disclose the true state of the U.S. EP segment's growth, leading to a severe loss of investor confidence and negatively impacting market expectations for future performance.
- Legal Rights Reminder: Faruq & Faruq LLP encourages anyone with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to come forward to assist in the litigation process.
See More
Boston Scientific Class Action Lawsuit Notice
- Class Action Timeline: Purchasers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, have until May 4, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor concern over potential legal risks.
- Allegations Overview: The lawsuit alleges that Boston Scientific and its executives made false or misleading statements during the class period, failing to disclose risks from increased market competition and unmet revenue expectations, which could undermine investor confidence.
- Financial Performance Disclosure: On February 4, 2026, Boston Scientific reported fourth-quarter and full-year 2025 results, revealing a net income increase to $672 million, yet the earnings per share (EPS) fell short of guidance, leading to a stock price drop of over 17%, reflecting market apprehension about the company's outlook.
- Legal Representation Information: Investors can apply to become lead plaintiffs through Robbins Geller Rudman & Dowd LLP, a firm with extensive experience in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strength in such cases.
See More
